For research use only. Not for therapeutic Use.
Delafloxacin(Cat No.:I006018)is a broad-spectrum fluoroquinolone antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). It inhibits bacterial DNA gyrase and topoisomerase IV, enzymes crucial for DNA replication and cell division. Delafloxacin demonstrates potent activity against both Gram-positive and Gram-negative bacteria, including resistant strains such as MRSA. Its dual anionic and cationic properties enhance tissue penetration and its stability under acidic conditions improves bioavailability. Delafloxacin is typically administered intravenously or orally, offering an effective treatment for serious infections, including those caused by resistant pathogens.
Catalog Number | I006018 |
CAS Number | 189279-58-1 (free) |
Synonyms | ABT-492; ABT 492; ABT492; RX-3341; RX3341; RX 3341; WQ-3034; WQ3034; WQ 3034; Delafloxacin, brand name. Baxdela.;1-(6-Amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
Molecular Formula | C18H12ClF3N4O4 |
Purity | ≥95% |
Solubility | Soluble in DMSO, not in water |
Storage | 0 - 4°C for short term ,or -20 °C for long term |
IUPAC Name | 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid |
InChI | InChI=1S/C18H12ClF3N4O4/c19-12-13-7(1-9(20)14(12)25-3-6(27)4-25)15(28)8(18(29)30)5-26(13)17-11(22)2-10(21)16(23)24-17/h1-2,5-6,27H,3-4H2,(H2,23,24)(H,29,30) |
InChIKey | DYDCPNMLZGFQTM-UHFFFAOYSA-N |
SMILES | C1C(CN1C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4=C(C=C(C(=N4)N)F)F)F)O |
Reference | </br> 1:Hoover R, Hunt T, Benedict M, Paulson SK, Lawrence L, Cammarata S, Sun E. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers. Clin Ther. 2016 Jan 1;38(1):53-65. doi: 10.1016/j.clinthera.2015.11.019. Epub 2015 Dec 21. PubMed PMID: 26718605. |